Zevra Therapeutics
ZVRA
38 hedge funds and large institutions have $5.86M invested in Zevra Therapeutics in 2019 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
19% more funds holding
Funds holding: 32 → 38 (+6)
58% less capital invested
Capital invested by funds: $13.9M → $5.86M (-$8.04M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$782K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$248K |
| 3 |
RFN
RDA Financial Network
Akron,
Iowa
|
+$159K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$96.9K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$75K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$748K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$39.9K |
| 3 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$24K |
| 4 |
Morgan Stanley
New York
|
-$10.3K |
| 5 |
BlackRock
New York
|
-$3.69K |
ZVRA Hedge Fund Activity: Q3 2019 in Review
38 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q3 2019, worth a combined $5.86M — down 58% from $13.9M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ZVRA positions and 2 closed out — a net gain of 7 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $782K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $748K sold.
- 38 institutional investors held Zevra Therapeutics (ZVRA) as of Q3 2019, up from 32 in Q2 2019.
- Funds reported $5.86M of Zevra Therapeutics stock for Q3 2019, down 58% quarter-over-quarter.
- 9 funds opened new Zevra Therapeutics positions in Q3 2019 and 2 closed out, a net change of +7 holders.
- The largest Zevra Therapeutics buyer in Q3 2019 was Deerfield Management, an estimated $782K added.
- The largest Zevra Therapeutics seller in Q3 2019 was Alyeska Investment Group, an estimated $748K sold.
Based on aggregated 13F filings for Q3 2019.